The benefits of combination therapy with esomeprazole and rebamipide in symptom improvement in reflux esophagitis

An international multicenter study

Su Jin Hong, Soo Heon Park, Jeong Seop Moon, Woon Geon Shin, Jae Gyu Kim, Yong Chan Lee, Dong Ho Lee, Jae Young Jang, Jae J. Kim, Hang Lak Lee, Sang Woo Lee, Young Hwangbo, Jianming Xu, Bangmao Wang, Zhanxiong Xue, Fei Liu, Yaozong Yuan, Somchai Leelakusolvong, Frederick Dy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis. Methods: A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group) or 40 mg esomeprazole daily (monotherapy group). We used a symptom questionnaire that evaluated heartburn, acid regurgitation, and four upper gastrointestinal symptoms. The primary efficacy end point was the mean decrease in the total symptom score. Results: The mean decreases in the total symptom score at 4 weeks were estimated to be -18.1±13.8 in the combination therapy group and -15.1±11.9 in the monotherapy group (p=0.011). Changes in reflux symptoms from baseline after 4 weeks of treatment were -8.4±6.6 in the combination therapy group and -6.8±5.9 in the monotherapy group (p=0.009). Conclusions: Over a 4-week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis than esomeprazole monotherapy.

Original languageEnglish
JournalGut and Liver
Volume10
Issue number6
DOIs
Publication statusPublished - 2016 Nov 1

Fingerprint

Esomeprazole
Peptic Esophagitis
Multicenter Studies
Group Psychotherapy
Therapeutics
Heartburn
rebamipide
Acids

Keywords

  • Esomeprazole
  • Heartburn
  • Peptic esophagitis
  • Rebamipide
  • Symptoms

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

The benefits of combination therapy with esomeprazole and rebamipide in symptom improvement in reflux esophagitis : An international multicenter study. / Hong, Su Jin; Park, Soo Heon; Moon, Jeong Seop; Shin, Woon Geon; Kim, Jae Gyu; Lee, Yong Chan; Lee, Dong Ho; Jang, Jae Young; Kim, Jae J.; Lee, Hang Lak; Lee, Sang Woo; Hwangbo, Young; Xu, Jianming; Wang, Bangmao; Xue, Zhanxiong; Liu, Fei; Yuan, Yaozong; Leelakusolvong, Somchai; Dy, Frederick.

In: Gut and Liver, Vol. 10, No. 6, 01.11.2016.

Research output: Contribution to journalArticle

Hong, SJ, Park, SH, Moon, JS, Shin, WG, Kim, JG, Lee, YC, Lee, DH, Jang, JY, Kim, JJ, Lee, HL, Lee, SW, Hwangbo, Y, Xu, J, Wang, B, Xue, Z, Liu, F, Yuan, Y, Leelakusolvong, S & Dy, F 2016, 'The benefits of combination therapy with esomeprazole and rebamipide in symptom improvement in reflux esophagitis: An international multicenter study', Gut and Liver, vol. 10, no. 6. https://doi.org/10.5009/gnl15537
Hong, Su Jin ; Park, Soo Heon ; Moon, Jeong Seop ; Shin, Woon Geon ; Kim, Jae Gyu ; Lee, Yong Chan ; Lee, Dong Ho ; Jang, Jae Young ; Kim, Jae J. ; Lee, Hang Lak ; Lee, Sang Woo ; Hwangbo, Young ; Xu, Jianming ; Wang, Bangmao ; Xue, Zhanxiong ; Liu, Fei ; Yuan, Yaozong ; Leelakusolvong, Somchai ; Dy, Frederick. / The benefits of combination therapy with esomeprazole and rebamipide in symptom improvement in reflux esophagitis : An international multicenter study. In: Gut and Liver. 2016 ; Vol. 10, No. 6.
@article{35638a887fff4cc1868433ca42d42070,
title = "The benefits of combination therapy with esomeprazole and rebamipide in symptom improvement in reflux esophagitis: An international multicenter study",
abstract = "Background/Aims: To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis. Methods: A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group) or 40 mg esomeprazole daily (monotherapy group). We used a symptom questionnaire that evaluated heartburn, acid regurgitation, and four upper gastrointestinal symptoms. The primary efficacy end point was the mean decrease in the total symptom score. Results: The mean decreases in the total symptom score at 4 weeks were estimated to be -18.1±13.8 in the combination therapy group and -15.1±11.9 in the monotherapy group (p=0.011). Changes in reflux symptoms from baseline after 4 weeks of treatment were -8.4±6.6 in the combination therapy group and -6.8±5.9 in the monotherapy group (p=0.009). Conclusions: Over a 4-week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis than esomeprazole monotherapy.",
keywords = "Esomeprazole, Heartburn, Peptic esophagitis, Rebamipide, Symptoms",
author = "Hong, {Su Jin} and Park, {Soo Heon} and Moon, {Jeong Seop} and Shin, {Woon Geon} and Kim, {Jae Gyu} and Lee, {Yong Chan} and Lee, {Dong Ho} and Jang, {Jae Young} and Kim, {Jae J.} and Lee, {Hang Lak} and Lee, {Sang Woo} and Young Hwangbo and Jianming Xu and Bangmao Wang and Zhanxiong Xue and Fei Liu and Yaozong Yuan and Somchai Leelakusolvong and Frederick Dy",
year = "2016",
month = "11",
day = "1",
doi = "10.5009/gnl15537",
language = "English",
volume = "10",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "6",

}

TY - JOUR

T1 - The benefits of combination therapy with esomeprazole and rebamipide in symptom improvement in reflux esophagitis

T2 - An international multicenter study

AU - Hong, Su Jin

AU - Park, Soo Heon

AU - Moon, Jeong Seop

AU - Shin, Woon Geon

AU - Kim, Jae Gyu

AU - Lee, Yong Chan

AU - Lee, Dong Ho

AU - Jang, Jae Young

AU - Kim, Jae J.

AU - Lee, Hang Lak

AU - Lee, Sang Woo

AU - Hwangbo, Young

AU - Xu, Jianming

AU - Wang, Bangmao

AU - Xue, Zhanxiong

AU - Liu, Fei

AU - Yuan, Yaozong

AU - Leelakusolvong, Somchai

AU - Dy, Frederick

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background/Aims: To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis. Methods: A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group) or 40 mg esomeprazole daily (monotherapy group). We used a symptom questionnaire that evaluated heartburn, acid regurgitation, and four upper gastrointestinal symptoms. The primary efficacy end point was the mean decrease in the total symptom score. Results: The mean decreases in the total symptom score at 4 weeks were estimated to be -18.1±13.8 in the combination therapy group and -15.1±11.9 in the monotherapy group (p=0.011). Changes in reflux symptoms from baseline after 4 weeks of treatment were -8.4±6.6 in the combination therapy group and -6.8±5.9 in the monotherapy group (p=0.009). Conclusions: Over a 4-week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis than esomeprazole monotherapy.

AB - Background/Aims: To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis. Methods: A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group) or 40 mg esomeprazole daily (monotherapy group). We used a symptom questionnaire that evaluated heartburn, acid regurgitation, and four upper gastrointestinal symptoms. The primary efficacy end point was the mean decrease in the total symptom score. Results: The mean decreases in the total symptom score at 4 weeks were estimated to be -18.1±13.8 in the combination therapy group and -15.1±11.9 in the monotherapy group (p=0.011). Changes in reflux symptoms from baseline after 4 weeks of treatment were -8.4±6.6 in the combination therapy group and -6.8±5.9 in the monotherapy group (p=0.009). Conclusions: Over a 4-week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis than esomeprazole monotherapy.

KW - Esomeprazole

KW - Heartburn

KW - Peptic esophagitis

KW - Rebamipide

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=84992602775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992602775&partnerID=8YFLogxK

U2 - 10.5009/gnl15537

DO - 10.5009/gnl15537

M3 - Article

VL - 10

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 6

ER -